Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bit Digital Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Bit Digital Inc trades at $1.63 (market cap $583.11M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 7.7× Bit Digital Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BTBT | |
|---|---|---|
Market Cap | $4.49B | $583.11M |
Sector | Health | Technology |
52-Week High | $28.06 | $4.22 |
52-Week Low | $20.06 | $1.27 |
Enterprise Value | $3.69B | $872.41M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BTBT trades at $1.74, up 5.45% in the past 24 hours, but faces bearish technical signals with 14 sell indicators. The company reported a net loss of $80.32 million in 2025 with a negative net income margin of -145.45%, though revenue reached $113.56 million. Recent news highlights a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase, signaling strategic moves in AI infrastructure and digital assets.
The outlook remains challenging due to persistent losses and high cash burn, but analyst consensus is 100% buy with potential from strategic investments. Key risks include execution on new ventures, competitive pressures, and reliance on financing amid negative operating cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
